$0.178
+0.056 (+31.56%)At close
SGMO News
SGMO Events
Sangamo Therapeutics Initiates Voluntary Chapter 11 Bankruptcy Reorganization
Sangamo Therapeutics (SGMO) announced that it has commenced voluntary Chapter 11 bankruptcy reorganization proceedings and entered into separate "stalking horse" asset sale agreements with Eli Lilly (LLY) and Astellas Pharma (ALPMF). Under the agreements, Lilly will bid for Sangamo's genomic platforms and prion disease program, while Astellas will bid for its Fabry disease program. The company has secured a commitment for debtor-in-possession financing from Northridge ATM, LLC to support its operations through the court-supervised auction and restructuring process. "Following a comprehensive review of available alternatives, we believe this process provides a clear framework to pursue value-maximizing transactions," said Sandy Macrae, CEO of Sangamo Therapeutics. "Our priority is to execute a disciplined and efficient sale process while supporting all of our stakeholders. We are also pleased to have signed agreements with two large pharmaceutical companies to serve as stalking horse bidders in the process, underscoring the strategic interest in our assets."
Sangamo Reports Q4 Revenue of $14.23M
Reports Q4 revenue $14.23M vs. $7.55M last year. "Sangamo continued to make significant pipeline progress since the start of 2025. Following positive topline results from our registrational STAAR study in Fabry disease, we are well advanced in the rolling submission of the BLA to the FDA under the Accelerated Approval pathway," said Sandy Macrae, CEO of Sangamo. "In 2025, we also became a clinical-stage neurology company, with recruitment having commenced in the Phase 1/2 STAND study in small fiber neuropathy, and we continued to demonstrate that we are a collaborator of choice for neurotropic capsids, with the announcement of our third STAC-BBB capsid license agreement."
Company's Financial Guidance Depends on Securing Additional Funding
The company said, "This financial guidance is subject to our ability to secure adequate additional funding for our current operating plan."
Sangamo Submits ST-920 for Accelerated Approval
Sangamo Therapeutics announced advancement of the rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920. Following initiation of the rolling submission in December 2025, Sangamo has now submitted the preclinical and clinical modules to the FDA for review. Rolling submission allows for completed modules of the BLA to be submitted and reviewed by the FDA on an ongoing basis rather than waiting for the entire BLA to be submitted at once. In addition, the antibody assay companion diagnostic, which is designed to screen patients for eligibility with isaralgagene civaparvovec, has been submitted to, and accepted by, the FDA's Center for Devices and Radiological Health seeking Premarket Approval.
Sangamo CFO Prathyusha Duraibabu Departs, Nikunj Jain Appointed Interim CFO
In a regulatory filing, Sangamo announced that on February 2, the employment of Prathyusha Duraibabu, the company's principal financial officer, terminated. Effective February 3, Nikunj Jain, Sangamo's Vice President, Finance and Corporate Controller and principal accounting officer, has been appointed to the position of Interim CFO and will serve as the company's principal financial officer.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。